Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 18,750 Shares

Insmed Incorporated (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 18,750 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $77.03, for a total transaction of $1,444,312.50. Following the transaction, the chief executive officer now owns 334,186 shares of the company's stock, valued at approximately $25,742,347.58. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

William Lewis also recently made the following trade(s):

• On Monday, March 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.79, for a total value of $1,458,562.50.
• On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $81.03, for a total value of $1,519,312.50.
• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total value of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.94, for a total transaction of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The stock was sold at an average price of $70.18, for a total transaction of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The shares were sold at an average price of $63.36, for a total transaction of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total transaction of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Price Performance

NASDAQ INSM traded up $1.15 during trading hours on Friday, reaching $79.92. The company's stock had a trading volume of 1,928,336 shares, compared to its average volume of 2,182,816. The firm has a market capitalization of $14.47 billion, a price-to-earnings ratio of -14.30 and a beta of 1.28. The company's 50-day moving average is $77.43 and its two-hundred day moving average is $73.80. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91.

Remove Ads

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. On average, equities analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

Hedge Funds Weigh In On Insmed

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INSM. Elequin Capital LP acquired a new position in shares of Insmed during the 4th quarter worth about $28,000. Steward Partners Investment Advisory LLC increased its stake in Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares in the last quarter. V Square Quantitative Management LLC raised its holdings in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 248 shares during the last quarter. Spire Wealth Management purchased a new position in shares of Insmed in the fourth quarter valued at approximately $47,000. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 411 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on INSM. Stifel Nicolaus reduced their price objective on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research note on Friday, February 21st. Royal Bank of Canada reiterated an "outperform" rating and issued a $100.00 price target on shares of Insmed in a report on Wednesday. Bank of America lifted their price objective on shares of Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a research note on Thursday. JPMorgan Chase & Co. increased their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research note on Friday, February 7th. Finally, HC Wainwright reissued a "buy" rating and set a $90.00 target price on shares of Insmed in a report on Friday, February 21st. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $94.00.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.